Lonza Biologics, Inc. – FDA 483, Apr 16, 2026
Lonza Biologics, Inc. in Portsmouth, NH, was inspected and received a Form 483 with three observations related to significant manufacturing and quality control deficiencies for their CASGEVY drug product. The inspection revealed a lack of process control over CASGEVY manufacturing, failures in preventing microbiological contamination of sterile products, and inadequate warehousing procedures for final drug product vials. These issues indicate a serious lack of adherence to good manufacturing practices.
ID · 7b621acc-25b2-419b-b47c-63946c125023
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.